A detailed history of Pro Share Advisors LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Pro Share Advisors LLC holds 13,256 shares of CVAC stock, worth $33,670. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,256
Previous 13,847 4.27%
Holding current value
$33,670
Previous $47,000 19.15%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.74 - $3.79 $1,619 - $2,239
-591 Reduced 4.27%
13,256 $38,000
Q2 2024

Aug 13, 2024

SELL
$2.31 - $4.99 $4,259 - $9,201
-1,844 Reduced 11.75%
13,847 $47,000
Q1 2024

May 08, 2024

BUY
$2.94 - $4.34 $4,083 - $6,028
1,389 Added 9.71%
15,691 $47,000
Q4 2023

Feb 14, 2024

SELL
$3.96 - $6.41 $37,730 - $61,074
-9,528 Reduced 39.98%
14,302 $60,000
Q3 2023

Nov 13, 2023

BUY
$6.5 - $10.77 $975 - $1,615
150 Added 0.63%
23,830 $162,000
Q2 2023

Aug 10, 2023

BUY
$6.69 - $12.25 $55,466 - $101,564
8,291 Added 53.88%
23,680 $246,000
Q1 2023

May 25, 2023

BUY
$6.38 - $12.5 $98,181 - $192,362
15,389 New
15,389 $107,000
Q4 2022

Feb 02, 2023

SELL
$5.75 - $8.5 $184 - $272
-32 Reduced 0.2%
15,738 $94,000
Q3 2022

Nov 04, 2022

BUY
$7.48 - $15.24 $9,005 - $18,348
1,204 Added 8.27%
15,770 $124,000
Q2 2022

Aug 01, 2022

SELL
$13.18 - $19.41 $63,408 - $93,381
-4,811 Reduced 24.83%
14,566 $198,000
Q1 2022

May 10, 2022

SELL
$14.73 - $35.25 $102,123 - $244,388
-6,933 Reduced 26.35%
19,377 $380,000
Q4 2021

Feb 08, 2022

BUY
$33.72 - $48.22 $887,173 - $1.27 Million
26,310 New
26,310 $903,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $476M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.